- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Liquid Biopsy to Identify CTCs and Guide Treatment Decisions in Bladder Cancer
A blood test performed before radical cystectomy in patients with urothelial cancer of the bladder could identify the presence of circulating tumor cells (CTCs), which are predictive of outcome, according to a new study.
A blood test performed before radical cystectomy in patients with urothelial cancer of the bladder could identify the presence of circulating tumor cells (CTCs), which are predictive of outcome, according to a new study.
This "liquid biopsy" could offer valuable guidance about treatment decisions, said Michael Rink, MD, from University Medical Center Hamburg-Eppendorf in Germany.
Dr. Rink presented the findings here at the European Association of Urology 29th Annual Congress.
"The presence of CTCs was a strong predictor of outcome in patients undergoing radical cystectomy for bladder cancer who did not receive adjuvant chemotherapy," he said. These patients should be counseled about preoperative CTC findings, he added.
Read the complete story here: http://bit.ly/1lEDzcV
Source: Medscape
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
